nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—ABCB1—peripheral nervous system neoplasm	0.363	1	CbGaD
Pomalidomide—PTGS2—Cisplatin—peripheral nervous system neoplasm	0.0473	0.111	CbGbCtD
Pomalidomide—PTGS2—Etoposide—peripheral nervous system neoplasm	0.0465	0.109	CbGbCtD
Pomalidomide—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0448	0.105	CbGbCtD
Pomalidomide—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0392	0.0919	CbGbCtD
Pomalidomide—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0392	0.0919	CbGbCtD
Pomalidomide—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0358	0.084	CbGbCtD
Pomalidomide—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0272	0.0637	CbGbCtD
Pomalidomide—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0235	0.0551	CbGbCtD
Pomalidomide—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0218	0.0512	CbGbCtD
Pomalidomide—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0175	0.0411	CbGbCtD
Pomalidomide—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0167	0.0392	CbGbCtD
Pomalidomide—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0156	0.0366	CbGbCtD
Pomalidomide—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0153	0.036	CbGbCtD
Pomalidomide—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.0105	0.0245	CbGbCtD
Pomalidomide—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.01	0.0235	CbGbCtD
Pomalidomide—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00919	0.0215	CbGbCtD
Pomalidomide—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00627	0.0147	CbGbCtD
Pomalidomide—Lenalidomide—ABCB1—peripheral nervous system neoplasm	0.00165	1	CrCbGaD
Pomalidomide—TNF—Death Receptor Signalling—TNFSF10—peripheral nervous system neoplasm	0.000394	0.0574	CbGpPWpGaD
Pomalidomide—TNF—EBV LMP1 signaling—IFNB1—peripheral nervous system neoplasm	0.000254	0.037	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IFNB1—peripheral nervous system neoplasm	0.000224	0.0326	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.000219	0.0319	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.000207	0.0301	CbGpPWpGaD
Pomalidomide—TNF—Monoamine Transport—TH—peripheral nervous system neoplasm	0.000194	0.0282	CbGpPWpGaD
Pomalidomide—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.00018	0.000891	CcSEcCtD
Pomalidomide—Anaemia—Etoposide—peripheral nervous system neoplasm	0.00018	0.000889	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.00018	0.000888	CcSEcCtD
Pomalidomide—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000179	0.000885	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000179	0.000883	CcSEcCtD
Pomalidomide—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000178	0.000878	CcSEcCtD
Pomalidomide—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000178	0.000878	CcSEcCtD
Pomalidomide—Insomnia—Vincristine—peripheral nervous system neoplasm	0.000178	0.000877	CcSEcCtD
Pomalidomide—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000177	0.000874	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000176	0.000868	CcSEcCtD
Pomalidomide—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000176	0.000867	CcSEcCtD
Pomalidomide—Vertigo—Etoposide—peripheral nervous system neoplasm	0.000175	0.000864	CcSEcCtD
Pomalidomide—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.000174	0.000861	CcSEcCtD
Pomalidomide—Pain—Alitretinoin—peripheral nervous system neoplasm	0.000174	0.00086	CcSEcCtD
Pomalidomide—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000174	0.00086	CcSEcCtD
Pomalidomide—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000174	0.000857	CcSEcCtD
Pomalidomide—Infection—Cisplatin—peripheral nervous system neoplasm	0.000172	0.000851	CcSEcCtD
Pomalidomide—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000172	0.000851	CcSEcCtD
Pomalidomide—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000171	0.000844	CcSEcCtD
Pomalidomide—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000171	0.000844	CcSEcCtD
Pomalidomide—Rash—Topotecan—peripheral nervous system neoplasm	0.000171	0.000843	CcSEcCtD
Pomalidomide—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000171	0.000843	CcSEcCtD
Pomalidomide—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000171	0.000842	CcSEcCtD
Pomalidomide—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.00017	0.00084	CcSEcCtD
Pomalidomide—Cough—Etoposide—peripheral nervous system neoplasm	0.00017	0.000839	CcSEcCtD
Pomalidomide—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.00017	0.000839	CcSEcCtD
Pomalidomide—Blood creatinine increased—Epirubicin—peripheral nervous system neoplasm	0.00017	0.000839	CcSEcCtD
Pomalidomide—Headache—Topotecan—peripheral nervous system neoplasm	0.00017	0.000838	CcSEcCtD
Pomalidomide—Rash—Tretinoin—peripheral nervous system neoplasm	0.000169	0.000837	CcSEcCtD
Pomalidomide—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000169	0.000837	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000169	0.000837	CcSEcCtD
Pomalidomide—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000169	0.000836	CcSEcCtD
Pomalidomide—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000169	0.000836	CcSEcCtD
Pomalidomide—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000169	0.000836	CcSEcCtD
Pomalidomide—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000169	0.000833	CcSEcCtD
Pomalidomide—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000833	CcSEcCtD
Pomalidomide—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000169	0.000832	CcSEcCtD
Pomalidomide—Hyponatraemia—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000832	CcSEcCtD
Pomalidomide—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000168	0.000831	CcSEcCtD
Pomalidomide—Headache—Tretinoin—peripheral nervous system neoplasm	0.000168	0.000831	CcSEcCtD
Pomalidomide—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000168	0.000829	CcSEcCtD
Pomalidomide—Pain—Vincristine—peripheral nervous system neoplasm	0.000168	0.000829	CcSEcCtD
Pomalidomide—Constipation—Vincristine—peripheral nervous system neoplasm	0.000168	0.000829	CcSEcCtD
Pomalidomide—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000828	CcSEcCtD
Pomalidomide—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000168	0.000828	CcSEcCtD
Pomalidomide—Rash—Melphalan—peripheral nervous system neoplasm	0.000167	0.000826	CcSEcCtD
Pomalidomide—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000167	0.000825	CcSEcCtD
Pomalidomide—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000166	0.000821	CcSEcCtD
Pomalidomide—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.000165	0.000815	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000165	0.000813	CcSEcCtD
Pomalidomide—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.000164	0.000809	CcSEcCtD
Pomalidomide—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000162	0.000801	CcSEcCtD
Pomalidomide—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000162	0.000799	CcSEcCtD
Pomalidomide—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000161	0.000795	CcSEcCtD
Pomalidomide—Nausea—Topotecan—peripheral nervous system neoplasm	0.000161	0.000795	CcSEcCtD
Pomalidomide—Confusional state—Etoposide—peripheral nervous system neoplasm	0.00016	0.000792	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.00016	0.00079	CcSEcCtD
Pomalidomide—Muscular weakness—Epirubicin—peripheral nervous system neoplasm	0.00016	0.00079	CcSEcCtD
Pomalidomide—Nausea—Tretinoin—peripheral nervous system neoplasm	0.00016	0.000788	CcSEcCtD
Pomalidomide—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.00016	0.000788	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000158	0.000781	CcSEcCtD
Pomalidomide—Infection—Etoposide—peripheral nervous system neoplasm	0.000158	0.00078	CcSEcCtD
Pomalidomide—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000158	0.000778	CcSEcCtD
Pomalidomide—Nausea—Melphalan—peripheral nervous system neoplasm	0.000158	0.000778	CcSEcCtD
Pomalidomide—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.000776	CcSEcCtD
Pomalidomide—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.00077	CcSEcCtD
Pomalidomide—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000156	0.000769	CcSEcCtD
Pomalidomide—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000155	0.000766	CcSEcCtD
Pomalidomide—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000155	0.000764	CcSEcCtD
Pomalidomide—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000154	0.000763	CcSEcCtD
Pomalidomide—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000154	0.000759	CcSEcCtD
Pomalidomide—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000154	0.000759	CcSEcCtD
Pomalidomide—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000754	CcSEcCtD
Pomalidomide—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000152	0.000749	CcSEcCtD
Pomalidomide—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000151	0.000745	CcSEcCtD
Pomalidomide—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000744	CcSEcCtD
Pomalidomide—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.00015	0.000742	CcSEcCtD
Pomalidomide—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.00015	0.000741	CcSEcCtD
Pomalidomide—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000741	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.00015	0.00074	CcSEcCtD
Pomalidomide—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	0.000149	0.000735	CcSEcCtD
Pomalidomide—Pain—Cisplatin—peripheral nervous system neoplasm	0.000148	0.000733	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.000731	CcSEcCtD
Pomalidomide—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.000731	CcSEcCtD
Pomalidomide—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000147	0.000724	CcSEcCtD
Pomalidomide—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000146	0.000722	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000719	CcSEcCtD
Pomalidomide—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000145	0.000714	CcSEcCtD
Pomalidomide—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000144	0.000712	CcSEcCtD
Pomalidomide—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000143	0.000706	CcSEcCtD
Pomalidomide—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000704	CcSEcCtD
Pomalidomide—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000142	0.0007	CcSEcCtD
Pomalidomide—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000142	0.0007	CcSEcCtD
Pomalidomide—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000698	CcSEcCtD
Pomalidomide—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000141	0.000695	CcSEcCtD
Pomalidomide—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000694	CcSEcCtD
Pomalidomide—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.00014	0.00069	CcSEcCtD
Pomalidomide—Infestation—Epirubicin—peripheral nervous system neoplasm	0.00014	0.00069	CcSEcCtD
Pomalidomide—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.00014	0.00069	CcSEcCtD
Pomalidomide—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000689	CcSEcCtD
Pomalidomide—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000139	0.000688	CcSEcCtD
Pomalidomide—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000139	0.000684	CcSEcCtD
Pomalidomide—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000138	0.000682	CcSEcCtD
Pomalidomide—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000138	0.00068	CcSEcCtD
Pomalidomide—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000678	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000137	0.000678	CcSEcCtD
Pomalidomide—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000137	0.000677	CcSEcCtD
Pomalidomide—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000137	0.000677	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000676	CcSEcCtD
Pomalidomide—TNF—Alzheimers Disease—PPP3R1—peripheral nervous system neoplasm	0.000137	0.0199	CbGpPWpGaD
Pomalidomide—Pain—Etoposide—peripheral nervous system neoplasm	0.000136	0.000671	CcSEcCtD
Pomalidomide—Constipation—Etoposide—peripheral nervous system neoplasm	0.000136	0.000671	CcSEcCtD
Pomalidomide—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000136	0.000671	CcSEcCtD
Pomalidomide—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.00067	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.000135	0.0197	CbGpPWpGaD
Pomalidomide—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000665	CcSEcCtD
Pomalidomide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000135	0.000665	CcSEcCtD
Pomalidomide—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000134	0.000663	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000653	CcSEcCtD
Pomalidomide—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000652	CcSEcCtD
Pomalidomide—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000651	CcSEcCtD
Pomalidomide—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000648	CcSEcCtD
Pomalidomide—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000131	0.000647	CcSEcCtD
Pomalidomide—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000646	CcSEcCtD
Pomalidomide—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000131	0.000644	CcSEcCtD
Pomalidomide—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000642	CcSEcCtD
Pomalidomide—Dizziness—Vincristine—peripheral nervous system neoplasm	0.00013	0.000641	CcSEcCtD
Pomalidomide—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00013	0.000639	CcSEcCtD
Pomalidomide—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000638	CcSEcCtD
Pomalidomide—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000638	CcSEcCtD
Pomalidomide—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000128	0.000634	CcSEcCtD
Pomalidomide—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000128	0.000634	CcSEcCtD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—TNFSF10—peripheral nervous system neoplasm	0.000128	0.0187	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000128	0.000631	CcSEcCtD
Pomalidomide—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000128	0.00063	CcSEcCtD
Pomalidomide—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000628	CcSEcCtD
Pomalidomide—CYP3A4—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.000127	0.0185	CbGpPWpGaD
Pomalidomide—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000626	CcSEcCtD
Pomalidomide—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000126	0.000621	CcSEcCtD
Pomalidomide—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000621	CcSEcCtD
Pomalidomide—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000125	0.000616	CcSEcCtD
Pomalidomide—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000125	0.000615	CcSEcCtD
Pomalidomide—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000612	CcSEcCtD
Pomalidomide—Rash—Vincristine—peripheral nervous system neoplasm	0.000124	0.000611	CcSEcCtD
Pomalidomide—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000124	0.00061	CcSEcCtD
Pomalidomide—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000124	0.00061	CcSEcCtD
Pomalidomide—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000609	CcSEcCtD
Pomalidomide—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000607	CcSEcCtD
Pomalidomide—Headache—Vincristine—peripheral nervous system neoplasm	0.000123	0.000607	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000604	CcSEcCtD
Pomalidomide—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000602	CcSEcCtD
Pomalidomide—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000121	0.000597	CcSEcCtD
Pomalidomide—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000119	0.000586	CcSEcCtD
Pomalidomide—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000117	0.000578	CcSEcCtD
Pomalidomide—Nausea—Vincristine—peripheral nervous system neoplasm	0.000117	0.000576	CcSEcCtD
Pomalidomide—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000575	CcSEcCtD
Pomalidomide—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000566	CcSEcCtD
Pomalidomide—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000565	CcSEcCtD
Pomalidomide—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000114	0.000563	CcSEcCtD
Pomalidomide—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000563	CcSEcCtD
Pomalidomide—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000562	CcSEcCtD
Pomalidomide—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000562	CcSEcCtD
Pomalidomide—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000558	CcSEcCtD
Pomalidomide—Chills—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000556	CcSEcCtD
Pomalidomide—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000112	0.000555	CcSEcCtD
Pomalidomide—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.00011	0.000545	CcSEcCtD
Pomalidomide—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000543	CcSEcCtD
Pomalidomide—Rash—Cisplatin—peripheral nervous system neoplasm	0.000109	0.00054	CcSEcCtD
Pomalidomide—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000109	0.00054	CcSEcCtD
Pomalidomide—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000539	CcSEcCtD
Pomalidomide—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000109	0.000537	CcSEcCtD
Pomalidomide—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000108	0.0157	CbGpPWpGaD
Pomalidomide—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000532	CcSEcCtD
Pomalidomide—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000522	CcSEcCtD
Pomalidomide—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.00052	CcSEcCtD
Pomalidomide—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000105	0.000519	CcSEcCtD
Pomalidomide—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000518	CcSEcCtD
Pomalidomide—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000517	CcSEcCtD
Pomalidomide—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000514	CcSEcCtD
Pomalidomide—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000103	0.000509	CcSEcCtD
Pomalidomide—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000502	CcSEcCtD
Pomalidomide—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000101	0.000499	CcSEcCtD
Pomalidomide—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000499	CcSEcCtD
Pomalidomide—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000498	CcSEcCtD
Pomalidomide—Rash—Etoposide—peripheral nervous system neoplasm	0.0001	0.000495	CcSEcCtD
Pomalidomide—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.0001	0.000495	CcSEcCtD
Pomalidomide—Headache—Etoposide—peripheral nervous system neoplasm	9.96e-05	0.000492	CcSEcCtD
Pomalidomide—Vertigo—Epirubicin—peripheral nervous system neoplasm	9.81e-05	0.000484	CcSEcCtD
Pomalidomide—Leukopenia—Epirubicin—peripheral nervous system neoplasm	9.78e-05	0.000483	CcSEcCtD
Pomalidomide—Back pain—Doxorubicin—peripheral nervous system neoplasm	9.77e-05	0.000483	CcSEcCtD
Pomalidomide—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	9.72e-05	0.00048	CcSEcCtD
Pomalidomide—Cough—Epirubicin—peripheral nervous system neoplasm	9.53e-05	0.000471	CcSEcCtD
Pomalidomide—Nausea—Etoposide—peripheral nervous system neoplasm	9.45e-05	0.000466	CcSEcCtD
Pomalidomide—TNF—Apoptosis—TNFSF10—peripheral nervous system neoplasm	9.41e-05	0.0137	CbGpPWpGaD
Pomalidomide—Anaemia—Doxorubicin—peripheral nervous system neoplasm	9.34e-05	0.000461	CcSEcCtD
Pomalidomide—Arthralgia—Epirubicin—peripheral nervous system neoplasm	9.3e-05	0.000459	CcSEcCtD
Pomalidomide—Anxiety—Epirubicin—peripheral nervous system neoplasm	9.27e-05	0.000457	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	9.24e-05	0.0135	CbGpPWpGaD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	9.23e-05	0.000456	CcSEcCtD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—BIRC5—peripheral nervous system neoplasm	9.16e-05	0.0133	CbGpPWpGaD
Pomalidomide—Vertigo—Doxorubicin—peripheral nervous system neoplasm	9.08e-05	0.000448	CcSEcCtD
Pomalidomide—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	9.05e-05	0.000447	CcSEcCtD
Pomalidomide—Confusional state—Epirubicin—peripheral nervous system neoplasm	8.99e-05	0.000444	CcSEcCtD
Pomalidomide—Infection—Epirubicin—peripheral nervous system neoplasm	8.86e-05	0.000437	CcSEcCtD
Pomalidomide—Cough—Doxorubicin—peripheral nervous system neoplasm	8.82e-05	0.000435	CcSEcCtD
Pomalidomide—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	8.74e-05	0.000432	CcSEcCtD
Pomalidomide—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	8.73e-05	0.000431	CcSEcCtD
Pomalidomide—Skin disorder—Epirubicin—peripheral nervous system neoplasm	8.66e-05	0.000427	CcSEcCtD
Pomalidomide—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	8.62e-05	0.000425	CcSEcCtD
Pomalidomide—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	8.6e-05	0.000425	CcSEcCtD
Pomalidomide—Anxiety—Doxorubicin—peripheral nervous system neoplasm	8.57e-05	0.000423	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	8.54e-05	0.000422	CcSEcCtD
Pomalidomide—PTGS2—C-MYB transcription factor network—CD34—peripheral nervous system neoplasm	8.36e-05	0.0122	CbGpPWpGaD
Pomalidomide—Confusional state—Doxorubicin—peripheral nervous system neoplasm	8.32e-05	0.000411	CcSEcCtD
Pomalidomide—Infection—Doxorubicin—peripheral nervous system neoplasm	8.19e-05	0.000405	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	8.12e-05	0.000401	CcSEcCtD
Pomalidomide—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	8.09e-05	0.000399	CcSEcCtD
Pomalidomide—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	8.07e-05	0.000399	CcSEcCtD
Pomalidomide—Insomnia—Epirubicin—peripheral nervous system neoplasm	8.06e-05	0.000398	CcSEcCtD
Pomalidomide—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	8.01e-05	0.000395	CcSEcCtD
Pomalidomide—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	7.97e-05	0.000394	CcSEcCtD
Pomalidomide—TNF—Apoptosis—PPP3R1—peripheral nervous system neoplasm	7.97e-05	0.0116	CbGpPWpGaD
Pomalidomide—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	7.95e-05	0.000392	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—NF1—peripheral nervous system neoplasm	7.76e-05	0.0113	CbGpPWpGaD
Pomalidomide—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	7.75e-05	0.000383	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IFNB1—peripheral nervous system neoplasm	7.72e-05	0.0112	CbGpPWpGaD
Pomalidomide—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	7.7e-05	0.00038	CcSEcCtD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—CASP3—peripheral nervous system neoplasm	7.69e-05	0.0112	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—PTPN11—peripheral nervous system neoplasm	7.69e-05	0.0112	CbGpPWpGaD
Pomalidomide—Fatigue—Epirubicin—peripheral nervous system neoplasm	7.68e-05	0.000379	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	7.66e-05	0.0112	CbGpPWpGaD
Pomalidomide—Constipation—Epirubicin—peripheral nervous system neoplasm	7.62e-05	0.000376	CcSEcCtD
Pomalidomide—Pain—Epirubicin—peripheral nervous system neoplasm	7.62e-05	0.000376	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—ABCB1—peripheral nervous system neoplasm	7.53e-05	0.011	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	7.51e-05	0.000371	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—PPP3R1—peripheral nervous system neoplasm	7.47e-05	0.0109	CbGpPWpGaD
Pomalidomide—Insomnia—Doxorubicin—peripheral nervous system neoplasm	7.46e-05	0.000368	CcSEcCtD
Pomalidomide—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	7.35e-05	0.000363	CcSEcCtD
Pomalidomide—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	7.35e-05	0.000363	CcSEcCtD
Pomalidomide—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	7.17e-05	0.000354	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	7.12e-05	0.000352	CcSEcCtD
Pomalidomide—Fatigue—Doxorubicin—peripheral nervous system neoplasm	7.11e-05	0.000351	CcSEcCtD
Pomalidomide—Constipation—Doxorubicin—peripheral nervous system neoplasm	7.05e-05	0.000348	CcSEcCtD
Pomalidomide—Pain—Doxorubicin—peripheral nervous system neoplasm	7.05e-05	0.000348	CcSEcCtD
Pomalidomide—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	7.05e-05	0.000348	CcSEcCtD
Pomalidomide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	6.95e-05	0.0101	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—CASP3—peripheral nervous system neoplasm	6.87e-05	0.01	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	6.8e-05	0.000336	CcSEcCtD
Pomalidomide—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	6.57e-05	0.000324	CcSEcCtD
Pomalidomide—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	6.52e-05	0.000322	CcSEcCtD
Pomalidomide—Asthenia—Epirubicin—peripheral nervous system neoplasm	6.4e-05	0.000316	CcSEcCtD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—CASP3—peripheral nervous system neoplasm	6.34e-05	0.00924	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—CASP3—peripheral nervous system neoplasm	6.34e-05	0.00924	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—BIRC5—peripheral nervous system neoplasm	6.34e-05	0.00923	CbGpPWpGaD
Pomalidomide—Pruritus—Epirubicin—peripheral nervous system neoplasm	6.31e-05	0.000311	CcSEcCtD
Pomalidomide—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	6.1e-05	0.000301	CcSEcCtD
Pomalidomide—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	6.08e-05	0.0003	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IFNB1—peripheral nervous system neoplasm	6.03e-05	0.00878	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	5.96e-05	0.00867	CbGpPWpGaD
Pomalidomide—Asthenia—Doxorubicin—peripheral nervous system neoplasm	5.92e-05	0.000292	CcSEcCtD
Pomalidomide—Dizziness—Epirubicin—peripheral nervous system neoplasm	5.89e-05	0.000291	CcSEcCtD
Pomalidomide—Pruritus—Doxorubicin—peripheral nervous system neoplasm	5.83e-05	0.000288	CcSEcCtD
Pomalidomide—TNF—Apoptosis—TNFSF10—peripheral nervous system neoplasm	5.76e-05	0.00839	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	5.72e-05	0.00833	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CNTN6—peripheral nervous system neoplasm	5.7e-05	0.00831	CbGpPWpGaD
Pomalidomide—Vomiting—Epirubicin—peripheral nervous system neoplasm	5.67e-05	0.00028	CcSEcCtD
Pomalidomide—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	5.64e-05	0.000279	CcSEcCtD
Pomalidomide—Rash—Epirubicin—peripheral nervous system neoplasm	5.62e-05	0.000277	CcSEcCtD
Pomalidomide—Dermatitis—Epirubicin—peripheral nervous system neoplasm	5.61e-05	0.000277	CcSEcCtD
Pomalidomide—Headache—Epirubicin—peripheral nervous system neoplasm	5.58e-05	0.000276	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—BDNF—peripheral nervous system neoplasm	5.56e-05	0.00809	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—peripheral nervous system neoplasm	5.52e-05	0.00804	CbGpPWpGaD
Pomalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—peripheral nervous system neoplasm	5.46e-05	0.00796	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	5.46e-05	0.00795	CbGpPWpGaD
Pomalidomide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	5.45e-05	0.000269	CcSEcCtD
Pomalidomide—Nausea—Epirubicin—peripheral nervous system neoplasm	5.29e-05	0.000261	CcSEcCtD
Pomalidomide—Vomiting—Doxorubicin—peripheral nervous system neoplasm	5.24e-05	0.000259	CcSEcCtD
Pomalidomide—Rash—Doxorubicin—peripheral nervous system neoplasm	5.2e-05	0.000257	CcSEcCtD
Pomalidomide—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	5.2e-05	0.000256	CcSEcCtD
Pomalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	5.18e-05	0.00754	CbGpPWpGaD
Pomalidomide—Headache—Doxorubicin—peripheral nervous system neoplasm	5.17e-05	0.000255	CcSEcCtD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—CASP3—peripheral nervous system neoplasm	4.97e-05	0.00724	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	4.94e-05	0.0072	CbGpPWpGaD
Pomalidomide—Nausea—Doxorubicin—peripheral nervous system neoplasm	4.9e-05	0.000242	CcSEcCtD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	4.83e-05	0.00704	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	4.61e-05	0.00671	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—NTRK1—peripheral nervous system neoplasm	4.58e-05	0.00666	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	4.53e-05	0.0066	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—MYC—peripheral nervous system neoplasm	4.45e-05	0.00648	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	4.45e-05	0.00647	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—peripheral nervous system neoplasm	4.41e-05	0.00642	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CDKN2A—peripheral nervous system neoplasm	4.2e-05	0.00611	CbGpPWpGaD
Pomalidomide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	4.19e-05	0.00611	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—BDNF—peripheral nervous system neoplasm	4.19e-05	0.0061	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	4.13e-05	0.00601	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	4.05e-05	0.0059	CbGpPWpGaD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	3.99e-05	0.00582	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—CASP3—peripheral nervous system neoplasm	3.83e-05	0.00557	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—CASP3—peripheral nervous system neoplasm	3.83e-05	0.00557	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	3.78e-05	0.00551	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	3.72e-05	0.00542	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—NRAS—peripheral nervous system neoplasm	3.7e-05	0.0054	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CASP3—peripheral nervous system neoplasm	3.64e-05	0.00531	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	3.62e-05	0.00527	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	3.44e-05	0.00502	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—BDNF—peripheral nervous system neoplasm	3.44e-05	0.00501	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—AKT1—peripheral nervous system neoplasm	3.44e-05	0.005	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—peripheral nervous system neoplasm	3.41e-05	0.00497	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—CASP3—peripheral nervous system neoplasm	3.39e-05	0.00494	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—HRAS—peripheral nervous system neoplasm	3.18e-05	0.00463	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—AKT1—peripheral nervous system neoplasm	3.09e-05	0.0045	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	3.06e-05	0.00445	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—AKT1—peripheral nervous system neoplasm	2.99e-05	0.00435	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—peripheral nervous system neoplasm	2.91e-05	0.00424	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—peripheral nervous system neoplasm	2.85e-05	0.00415	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	2.85e-05	0.00415	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—MYC—peripheral nervous system neoplasm	2.85e-05	0.00414	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—NRAS—peripheral nervous system neoplasm	2.84e-05	0.00414	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—TP53—peripheral nervous system neoplasm	2.83e-05	0.00413	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	2.8e-05	0.00408	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NCAM1—peripheral nervous system neoplasm	2.79e-05	0.00406	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CASP3—peripheral nervous system neoplasm	2.78e-05	0.00404	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—AKT1—peripheral nervous system neoplasm	2.77e-05	0.00403	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—HRAS—peripheral nervous system neoplasm	2.71e-05	0.00395	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—AKT1—peripheral nervous system neoplasm	2.69e-05	0.00392	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—peripheral nervous system neoplasm	2.6e-05	0.00378	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	2.55e-05	0.00372	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—TP53—peripheral nervous system neoplasm	2.45e-05	0.00357	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	2.34e-05	0.00341	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—peripheral nervous system neoplasm	2.34e-05	0.0034	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	2.3e-05	0.00335	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.27e-05	0.00331	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	2.24e-05	0.00326	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CASP3—peripheral nervous system neoplasm	2.23e-05	0.00325	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	2.22e-05	0.00323	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MYC—peripheral nervous system neoplasm	2.17e-05	0.00316	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—CASP3—peripheral nervous system neoplasm	2.09e-05	0.00305	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	2.08e-05	0.00303	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—HRAS—peripheral nervous system neoplasm	2.08e-05	0.00303	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	1.99e-05	0.00289	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—AKT1—peripheral nervous system neoplasm	1.97e-05	0.00287	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—AKT1—peripheral nervous system neoplasm	1.97e-05	0.00287	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	1.95e-05	0.00284	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	1.92e-05	0.0028	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—NRAS—peripheral nervous system neoplasm	1.89e-05	0.00275	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	1.89e-05	0.00275	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—AKT1—peripheral nervous system neoplasm	1.83e-05	0.00267	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	1.81e-05	0.00264	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	1.78e-05	0.00259	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—MYC—peripheral nervous system neoplasm	1.76e-05	0.00256	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—NRAS—peripheral nervous system neoplasm	1.75e-05	0.00256	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	1.73e-05	0.00252	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CASP3—peripheral nervous system neoplasm	1.72e-05	0.0025	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	1.69e-05	0.00246	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	1.68e-05	0.00244	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	1.66e-05	0.00241	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MYC—peripheral nervous system neoplasm	1.63e-05	0.00238	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	1.61e-05	0.00235	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.61e-05	0.00234	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	1.55e-05	0.00226	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.53e-05	0.00223	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.47e-05	0.00215	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—peripheral nervous system neoplasm	1.43e-05	0.00208	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—HRAS—peripheral nervous system neoplasm	1.38e-05	0.00201	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—peripheral nervous system neoplasm	1.34e-05	0.00195	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MYC—peripheral nervous system neoplasm	1.34e-05	0.00195	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MET—peripheral nervous system neoplasm	1.33e-05	0.00194	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GNS—peripheral nervous system neoplasm	1.32e-05	0.00193	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—AKT1—peripheral nervous system neoplasm	1.32e-05	0.00192	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	1.29e-05	0.00187	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.29e-05	0.00187	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.27e-05	0.00186	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	1.27e-05	0.00184	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PTPN11—peripheral nervous system neoplasm	1.23e-05	0.00179	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.21e-05	0.00176	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—AKT1—peripheral nervous system neoplasm	1.21e-05	0.00176	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	1.17e-05	0.0017	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	1.13e-05	0.00165	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GNS—peripheral nervous system neoplasm	1.11e-05	0.00162	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	1.1e-05	0.0016	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.09e-05	0.00158	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NME1—peripheral nervous system neoplasm	1.06e-05	0.00155	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	1.05e-05	0.00153	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—COX2—peripheral nervous system neoplasm	1.02e-05	0.00149	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.02e-05	0.00149	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	9.92e-06	0.00144	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—ERBB2—peripheral nervous system neoplasm	9.73e-06	0.00142	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PPP3R1—peripheral nervous system neoplasm	9.26e-06	0.00135	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	9.12e-06	0.00133	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	9.12e-06	0.00133	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.68e-06	0.00126	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	8.28e-06	0.00121	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	8.2e-06	0.00119	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ENO2—peripheral nervous system neoplasm	8.02e-06	0.00117	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	7.86e-06	0.00115	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	7.54e-06	0.0011	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	7.49e-06	0.00109	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NRAS—peripheral nervous system neoplasm	7.4e-06	0.00108	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	7.26e-06	0.00106	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	7.21e-06	0.00105	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ENO2—peripheral nervous system neoplasm	6.72e-06	0.000979	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	6.7e-06	0.000976	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	6.6e-06	0.000961	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SLC2A1—peripheral nervous system neoplasm	6.47e-06	0.000942	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	6.47e-06	0.000942	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	6.32e-06	0.000921	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	6.28e-06	0.000914	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	6.02e-06	0.000876	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	5.79e-06	0.000844	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—BCHE—peripheral nervous system neoplasm	5.68e-06	0.000827	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.42e-06	0.000789	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HRAS—peripheral nervous system neoplasm	5.42e-06	0.000789	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TH—peripheral nervous system neoplasm	5.34e-06	0.000777	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	5.31e-06	0.000773	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	4.84e-06	0.000705	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—AKT1—peripheral nervous system neoplasm	4.78e-06	0.000696	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	4.76e-06	0.000694	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	4.64e-06	0.000676	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	4.48e-06	0.000653	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	4.47e-06	0.000651	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GNAS—peripheral nervous system neoplasm	4.36e-06	0.000635	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ABCB1—peripheral nervous system neoplasm	4.28e-06	0.000623	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	4.02e-06	0.000586	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.84e-06	0.000559	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	3.8e-06	0.000554	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	3.78e-06	0.000551	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PTPN11—peripheral nervous system neoplasm	3.62e-06	0.000527	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	3.21e-06	0.000468	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	3.09e-06	0.00045	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.06e-06	0.000446	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	3.02e-06	0.00044	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	2.93e-06	0.000427	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERBB2—peripheral nervous system neoplasm	2.86e-06	0.000416	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	2.48e-06	0.000361	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	2.47e-06	0.000359	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	2.42e-06	0.000352	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.37e-06	0.000345	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	2.33e-06	0.00034	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NRAS—peripheral nervous system neoplasm	2.17e-06	0.000317	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—peripheral nervous system neoplasm	2.03e-06	0.000295	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.9e-06	0.000277	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.87e-06	0.000272	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HRAS—peripheral nervous system neoplasm	1.59e-06	0.000232	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKT1—peripheral nervous system neoplasm	1.4e-06	0.000205	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKT1—peripheral nervous system neoplasm	1.18e-06	0.000171	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	8.34e-07	0.000121	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	6.66e-07	9.69e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	5.14e-07	7.48e-05	CbGpPWpGaD
